Condition: Neuromyelitis Optica Spectrum Disorders · Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
This description comes directly from the study's public registry record.
FuDong Shi · 0086-010-59978555 · ttyyirb@163.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital，Capital Medical University | Beijing, China | Recruiting |
| Beijing Tiantan Hospital，Capital Medical University | Beijing, China | Recruiting |
| Beijing Tongren Hospital, Capital Medical University | Beijing, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| The First Medical Center of PLA General Hospital | Beijing, China | Recruiting |
| The Third Medical Center of PLA General Hospital | Beijing, China | Recruiting |
| Cangzhou Central Hospital | Cangzhou, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, China | Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, China | Recruiting |
| Guangzhou First People's Hospital | Guangzhou, China | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06413654